WebNov 2, 2024 · The study showed that patients who underwent surgery after EGFR-TKI treatment had significantly better OS than patients who continued on EGFR-TKI treatment … WebApr 10, 2024 · Recently, intrathecal chemotherapy with pemetrexed (IP) was reported to be an alternative treatment in patients with NSCLC and LM. The results from a phase I/II trial examining the efficacy and safety of IP in patients with EGFR-mutant NSCLC after the failure of previous TKI, and 83% of study enrollees received osimertinib before IP.
Tyrosine Kinase Inhibitors - StatPearls - NCBI Bookshelf
WebFeb 14, 2014 · A number of tyrosine kinase inhibitors (TKIs), predominantly those targeting angiogenesis, are recommended to be discontinued pre-surgery or in the event of … Web2 days ago · Localized gastrointestinal stromal tumor is treated with surgery ... TKI treatment showed the development of pericardial effusion, which could be a life-threatening complication. Although reported cases of TKI-related effusions mostly associated with pleural effusion, concurrent or isolated pericardial effusion have been reported as well. ... overall cap rate vs terminal cap rate
The role of targeted therapy (TKI) in the treatment of advanced ...
WebAug 17, 2024 · This is the third in a series of four articles that review recent literature on cutaneous adverse reactions experienced with commonly prescribed biologic and targeted therapies, specifically small-molecule tyrosine kinase inhibitors (TKIs). Small-molecule tyrosine kinase inhibitors WebInstead, it may be reasonable to continue EGFR TKI beyond progression or add chemotherapy, radiotherapy, local surgery, or best supportive care, etc. It has been reported that continued treatment with EGFR TKI beyond progression benefits patients with activating EGFR mutations. 7, 8. WebJan 18, 2024 · ALK-TKI-naive patients were enrolled in cohort 1; cohort 2 included patients who experienced intracranial progression with or without extracranial progression after treatment with crizotinib; and patients who developed progression only in CNS following treatment with other second-generation ALK inhibitors (ceritinib, CT707, WX-0593) were ... overall care